Yes, Anifrolumab is FDA approved. The U.S. Food and Drug Administration (FDA) approved Anifrolumab for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults on July 30, 2021. This approval provides a new option for patients with SLE who are already receiving standard treatment.
Anifrolumab is specifically used to treat adults with moderate to severe systemic lupus erythematosus (SLE). It is designed to be used in conjunction with standard SLE treatments to help manage the symptoms of this autoimmune disease.
Anifrolumab is administered as follows:
While Anifrolumab is effective, it can cause side effects. Common side effects include:
Serious side effects that require immediate medical attention include:
Before starting treatment with Anifrolumab, consider the following precautions:
Anifrolumab offers a new treatment option for adults with moderate to severe systemic lupus erythematosus (SLE). It is essential to follow the prescribed administration guidelines and take necessary precautions to minimize side effects and ensure effective treatment. Always consult with a healthcare provider for personalized medical advice and treatment plans.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!